Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Queensland Health
Healthtrust
Farmers Insurance
Dow
Julphar
Cantor Fitzgerald
Baxter
US Department of Justice

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,946,207

« Back to Dashboard

Summary for Patent: 8,946,207
Title:Processes for preparing 3-benzazepines
Abstract: The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
Inventor(s): Wolgast; Beverly L. (San Diego, CA), Gilson, III; Charles A. (San Diego, CA), Aytes; Shelley (San Diego, CA), Estrada; Scott A. (La Jolla, CA), Sengupta; Dipanjan (San Diego, CA), Smith; Brian (San Diego, CA), Rey; Max (Wallisellen, CH), Weigl; Ulrich (Hilzingen, DE)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/619,773
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,946,207

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,946,207

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,704,993 Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases ➤ Sign Up
9,102,627 Processes for preparing 3-benzazepines ➤ Sign Up
8,367,657 Processes for preparing 3-benzazepines ➤ Sign Up
8,404,675 Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,946,207

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2332921 ➤ Sign Up
New Zealand 578503 ➤ Sign Up
Mexico PA05013366 ➤ Sign Up
Mexico PA05013364 ➤ Sign Up
South Korea 20060023163 ➤ Sign Up
South Korea 20060023156 ➤ Sign Up
Japan 2014133771 ➤ Sign Up
Japan 2011162564 ➤ Sign Up
Japan 5667593 ➤ Sign Up
Japan 2012107067 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Accenture
UBS
Colorcon
Teva
McKesson
McKinsey
Julphar
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot